Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model. - Wikidata - wikimedia - TriplyDB

Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.

Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.

http://www.wikidata.org/entity/Q34761229

about

c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives Protein Kinases and Parkinson's Disease c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration.Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death.The capable ABL: what is its biological function?Ever-advancing chronic myeloid leukemia treatment.Protein phosphorylation in neurodegeneration: friend or foe?Nilotinib - Differentiating the Hope from the Hype.Autophagy regulates MAVS signaling activation in a phosphorylation-dependent manner in microglia.The c-Abl inhibitor in Parkinson disease.The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes.Transformer 2β and miR-204 regulate apoptosis through competitive binding to 3' UTR of BCL2 mRNA.A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease.Isolation and Culture of Brain Microvascular Endothelial Cells for In Vitro Blood-Brain Barrier Studies.c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.c-Abl-mediated Drp1 phosphorylation promotes oxidative stress-induced mitochondrial fragmentation and neuronal cell death.Reduction of Blood Amyloid-β Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition.The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.

P2860

Q24318974-2FA0EF82-B973-4840-A805-0337CF5D7119 Q26747508-C381DE36-ECD6-43F5-A36A-238BC6EB8D3A Q28067636-84806F0B-A3B9-455A-9324-8272A68351E9 Q28070292-E75AA5E5-E8B6-46C7-8034-293A2EBBA598 Q34025103-75CADD11-B6B1-42F6-A7E3-F2726EC4FB0D Q35701794-2A157C28-FA36-4B3D-8D16-8726D26AEF55 Q36079187-DFD67DA0-1960-4B34-899D-B74651AAF77E Q37137895-1D4618E0-947E-444B-BAD2-47E4FD7A19F2 Q37354028-C3AA2561-B2EF-4B4C-AF60-D786DEC7EFF8 Q37713585-768CF1A2-3674-4DC1-BFCF-4DDA02085C64 Q38164565-56FD8470-9B4D-451C-93F6-2699A077D251 Q38214594-9AAF7255-A699-4226-AD36-A9642EA74B84 Q38840128-0A1BA9B7-FF66-434D-A148-DC4786DD1698 Q38988911-A2BC473C-73C8-495C-8D5A-FBA0C1B4EED3 Q39081447-85C455C0-7E4A-4D9F-B1CE-2D859AC91F37 Q39136811-E9114F0B-7A13-49CE-BEB2-E0C1B20C1E19 Q39264622-859C1574-7D98-402C-83C6-DB08B3BF7E50 Q39468971-9B663F5F-7AE3-415E-94B0-BCA2AAD428F1 Q41967371-0A9A1C5E-3C12-4D7E-A881-C7E437AC50F8 Q46244825-6BD51EE3-5C11-438B-AC64-3929069AD54E Q47124745-715AC400-EA7E-4555-97E7-A81C5688A5DD Q47133507-80828B0D-92CE-438C-8E98-43A3B17A8CAA Q48547723-EB91F8AF-BD0C-486A-ADD0-C4FBED1F5C4D Q55401120-5874B5EC-6A30-4ABB-AD90-79B5237A415A

P2860

Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.

http://www.wikidata.org/entity/Q34761229

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@ast

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@en

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@nl

type

label

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@ast

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@en

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@nl

prefLabel

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@ast

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@en

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@nl

P1433

Q34761229-8169BBC2-9CDC-459F-852F-C42050C745ED

P1476

Q34761229-C727CA30-0B32-40E4-884B-F7D0E0092CD0

P2093

Q34761229-2682AB6F-2475-4B96-A55F-3E862153DD4D

Q34761229-5B3473F9-0B02-4997-AFB5-7D15FA2D88F5

Q34761229-7C2FC1F2-80D0-4F5B-BEDB-9F028F95F71A

Q34761229-9B216962-93D3-4959-9B3F-FA58DD885B58

Q34761229-BE72D829-FBC3-4FF8-881D-D5E973F35618

Q34761229-C2ACFB0D-7FBA-432B-B8FE-E22A89BDA981

Q34761229-CA1EAF49-F32C-416C-BB43-8454210F8E93

Q34761229-E8844A5C-AD96-4AA8-B49E-FD08727B9342

Q34761229-F0EF1092-64E9-4278-A77C-A31DBFDE9D35

P2860

Q34761229-06FE0FB0-E4C7-4CF8-8645-6E2E3FC2938B

Q34761229-0ADB6E34-E136-4E3A-A044-26640BDAFBCB

Q34761229-0DF808E8-816B-4F19-ADFA-7EB90CBA74DC

Q34761229-245BD3ED-2BD2-494D-BBAE-2E2204E54A7C

Q34761229-4DDDC157-E2E1-4BF2-8AFF-70581313979E

Q34761229-4E1CFA6A-444E-4520-9170-8A3F72A42C6D

Q34761229-5151981B-CEC6-43C2-8D08-1B19CB1DF911

Q34761229-57900F5D-048E-47D9-95F4-363054DAF0EE

Q34761229-5AAF881B-63B5-46FE-9447-607495BE49F1

Q34761229-5DE8A830-3D12-439E-BE95-4320359F4088

P304

Q34761229-C87E293E-83D7-4ECD-AA0B-00FBCF233A56

P31

Q34761229-5D035279-610E-4A0B-A8F9-319322C751CB

P356

Q34761229-47A83825-8C01-4465-84D3-4BC5B16181C5

P407

Q34761229-C6CF003E-17AA-4806-8687-0AD27D476518

P433

Q34761229-A6201076-6EF2-4AAF-B6F5-43FF3A6077E7

P478

Q34761229-A77ED885-5499-4F65-9406-ECBEED8E449C

P577

Q34761229-BC8C3CAD-2201-4DBE-9EFE-B74E48912AA3

P5875

Q34761229-08C1A380-F846-4F3F-A8A2-109A7F950DC6

P698

Q34761229-5B7FCDB7-89F9-4B4A-A48F-7629AFE161B6

P921

Q34761229-7C94D6D3-A535-43B7-B842-0A627C52C78F

P932

Q34761229-F4EF43AB-1894-44D9-A156-1EB34C08F631

P356

JOURNAL.PONE.0065129

P1433

P1476

Neuroprotective efficacy of a ...... ine Parkinson's disease model.

@en

P2093

Merle G Paule

http://www.w3.org/2001/XMLSchema#string

Robert A Clark

http://www.w3.org/2001/XMLSchema#string

Senlin Li

http://www.w3.org/2001/XMLSchema#string

Shinya Kimura

http://www.w3.org/2001/XMLSchema#string

Syed F Ali

http://www.w3.org/2001/XMLSchema#string

Syed Z Imam

http://www.w3.org/2001/XMLSchema#string

William Slikker

http://www.w3.org/2001/XMLSchema#string

William Trickler

http://www.w3.org/2001/XMLSchema#string

Zbigniew K Binienda

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

Dopamine covalently modifies and functionally inactivates parkin

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function

Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species

Parkinson's disease: mechanisms and models

Association between early-onset Parkinson's disease and mutations in the parkin gene

Molecular pathways of neurodegeneration in Parkinson's disease

Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.

P304

e65129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0065129

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237061229

http://www.w3.org/2001/XMLSchema#string

P698

23741470

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3669292

http://www.w3.org/2001/XMLSchema#string